Shilpa Medicare Q3 FY26 results: consolidated PAT more than doubles YoY

Pat Growth 25pctExceptional ItemResults RestatedResults View source PDF Explain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.1%Reaction day

₹316.50

prior close

₹311.60

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.8%+1.9% vs market

Pharmaceuticals peers, median of 159sector-0.6%+1.7% vs sector

On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.3

10m

+1.7

15m

+2.4

30m

+0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.1-0.8+1.9-0.6+1.7

Next day

+5.2+1.8+3.4+1.1+4.1

+7.1+2.8+4.3+1.7+5.5

+4.6+2.3+2.3+1.3+3.3

+2.1+1.8+0.3+0.5+1.6

+3.0+0.3+2.8+0.0+3.0

+4.6+0.5+4.1-0.2+4.8

15d

+6.0-2.5+8.5-2.7+8.7

+4.6-6.3+10.9-4.6+9.2

+23.9-8.0+31.8-7.4+31.2

+39.3+8.3+31.1+2.6+36.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q3 FY26 consolidated revenue Rs 41,054 lakhs vs Rs 32,048 lakhs YoY. 9M FY26 consolidated PAT surged to Rs 13,553 lakhs from Rs 6,379 lakhs, more than double. Standalone 9M PAT Rs 6,746 lakhs vs Rs 7,352 lakhs YoY. Q3 standalone PAT Rs 1,593 lakhs. Exceptional loss Rs 220 lakhs Q3 and Rs 895 lakhs 9M standalone from foreign subsidiary impairments and new labour code gratuity impact. Audit Committee reconstituted with new member. Results restated for INM Technologies merger.

Likely market impact

Strong 9M consolidated profit growth driven by subsidiaries turnaround. Standalone softer with exceptional items dragging PAT. Monitor subsidiary recovery.